Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alnylam Pharmaceut (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,400,975
  • Shares Outstanding, K 101,177
  • Annual Sales, $ 74,910 K
  • Annual Income, $ -761,500 K
  • 36-Month Beta 2.54
  • Price/Sales 112.15
  • Price/Cash Flow N/A
  • Price/Book 5.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -2.15
  • Number of Estimates 4
  • High Estimate -2.10
  • Low Estimate -2.20
  • Prior Year -1.41
  • Growth Rate Est. (year over year) -52.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.29 +12.44%
on 02/08/19
86.45 -3.38%
on 02/05/19
+3.08 (+3.83%)
since 01/15/19
3-Month
60.27 +38.59%
on 12/24/18
90.70 -7.91%
on 01/11/19
+14.16 (+20.41%)
since 11/15/18
52-Week
60.27 +38.59%
on 12/24/18
153.99 -45.75%
on 03/20/18
-38.21 (-31.39%)
since 02/15/18

Most Recent Stories

More News
Detailed Research: Economic Perspectives on DXC Technology, AMC Networks, SunCoke Energy Partners, Alnylam Pharmaceuticals, Amtech, and Diamond Hill Investment Group -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of DXC Technology Company....

ASYS : 4.90 (+1.24%)
SXCP : 14.31 (+3.17%)
DHIL : 151.41 (-0.55%)
ALNY : 83.53 (+0.60%)
DXC : 65.46 (+0.26%)
SXC : 9.87 (+2.71%)
AMCX : 64.46 (+2.25%)
Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates

Alnylam (ALNY) incurs wider year-over-year loss in the fourth quarter of 2018.

MDCO : 24.77 (+3.17%)
ALNY : 83.53 (+0.60%)
BMY : 51.67 (+1.65%)
SNY : 42.55 (+2.38%)
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 7.61% and 67.92%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

ALNY : 83.53 (+0.60%)
Alnylam: 4Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $211.4 million in its fourth quarter.

ALNY : 83.53 (+0.60%)
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity

--a^' Obtained Regulatory Alignment on APOLLO-B Phase 3 Study of Patisiran in ATTR Amyloidosis with Cardiomyopathy and Initiated HELIOS-A Phase 3 Study to Advance Vutrisiran to Market, Supporting Plan...

ALNY : 83.53 (+0.60%)
Alnylam Announces Publication of Phase 1 Givosiran Data in The New England Journal of Medicine

--a^' Givosiran also Associated with Reduced Rate of Porphyria Attacks and Hemin Use -

ALNY : 83.53 (+0.60%)
Alnylam to Webcast Presentations at Upcoming February Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:

ALNY : 83.53 (+0.60%)
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December...

ALNY : 83.53 (+0.60%)
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics

NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged...

ALNY : 83.53 (+0.60%)
Watch for Alnylam Pharmace to Potentially Rebound After Falling 9.33% Yesterday

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $75.30 to a high of $78.46. Yesterday, the shares fell 9.3%, which took the trading range below the 3-day low of...

ALNY : 83.53 (+0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade ALNY with:

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

2nd Resistance Point 84.84
1st Resistance Point 84.19
Last Price 83.53
1st Support Level 82.45
2nd Support Level 81.36

See More

52-Week High 153.99
Fibonacci 61.8% 118.19
Fibonacci 50% 107.13
Fibonacci 38.2% 96.07
Last Price 83.53
52-Week Low 60.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar